Navigation Links
Research suggests molecular 'switch' may play role in tumor suppression
Date:1/13/2013

BLOOMINGTON, Ind. -- Newly published research by Indiana University structural biologist Joel Ybe and colleagues identifies a "topology switch" in the protein clathrin, the function of which may shed light on molecular processes involved in tumor suppression.

The paper, available in and featured on the front cover of the Jan. 16, 2013, issue of FEBS Letters, a journal of the Federation of European Biochemical Societies, could broaden scientists' understanding of the importance of clathrin and potentially lead to new strategies for controlling cancer.

"This is a totally unexpected but wonderful finding," Ybe said. "It has exciting implications for understanding the role that clathrin may play in the growth or suppression of tumors."

Ybe is a senior research scientist in the Department of Molecular and Cellular Biochemistry in the IU College of Arts and Sciences. Co-authors of the paper are postdoctoral researchers Sarah Fontaine and Xiaoyan Lin; IU chemist Todd Stone; Sanjay Mishra, formerly at IU and now at Vanderbilt University; and Jay Nix of Lawrence Berkeley National Laboratory.

Typically found in a three-legged form called a trimer, clathrin is best understood for its role in endocytosis, the process by which cells absorb proteins and other molecules. But recent research has suggested that clathrin in a one-legged form, or monomer, may have a role in suppressing tumors. Ybe and his team show how a "switch" in clathrin can be flipped to produce non-trimeric clathrin molecules.

"Clathrin is known to function as a trimer in receptor-mediated endocytosis, but the existence of the monomeric form and its role in tumor suppression is less well-accepted," said Alexandra Ainsztein, who oversees membrane trafficking grants at the National Institute of General Medical Sciences of the National Institutes of Health. "By providing evidence for a model in which a molecular shift de-trimerizes clathrin and changes its cellular distribution, this work will spur further research into unanticipated roles for this important molecule in healthy and diseased cells."

In endocytosis, trimeric clathrin molecules bind together to form molecular packages that allow other substances to enter cells. Several years ago, researchers in Japan published evidence that clathrin can also serve as an activator of the protein p53, a known tumor suppressor.

For the activation to take place, clathrin and p53 must both be present in the cell's nucleus. The catch is that clathrin molecules cannot penetrate the nucleus in their usual, three-legged form. To enter, the three-legged clathrin molecule must be altered or "de-trimerized."

Using X-ray crystallography, Ybe and his team discovered a "topology switch" in the clathrin molecule. They showed they could break the switch by mutating one key amino acid that is part of the switch. The result: Clathrin was "detrimerized"; three-legged molecules were broken into one-legged ones.

Experimenting with both cancer and non-cancer cells, the researchers found the three-legged clathrin only in the cytoplasm of the cells, not the nucleus. But with the "switch" broken, clathrin formed monomers and was also present in the nucleus, where it could potentially activate tumor suppression.

Ybe said the results point to the need for additional research to better understand the structure and function of clathrin and the role it plays in cellular processes, including those involved in cancer. With the clathrin "switch" identified, researchers can attempt to better understand how it can be activated, with the goal of developing new therapies for suppressing the growth of tumors. Ybe has a patent pending on the idea to use the mutated form of clathrin to stimulate the natural anti-cancer activities of human cells.

The finding developed from Ybe's research on the role of clathrin in Huntington's disease, a genetic disorder that causes neurological degeneration and is estimated to affect about 15,000 people in the U.S. The National Institutes of Health awarded the project a $1.2 million, four-year grant in 2009. The NIH grant number is R01GM064387.


'/>"/>

Contact: Steve Hinnefeld
slhinnef@iu.edu
812-856-3488
Indiana University
Source:Eurekalert

Related medicine news :

1. Canada In Vitro Diagnostics Market Analysis and Forecasts to 2017 in New Research Report at RnRMarketResearch.com
2. ZijaExtreme.com Researches Vitamin D Deficiency & Using a More Natural Approach
3. Spectacles Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
4. Game-based economics research explains why we roll the dice on flu shots
5. Experts aim to redefine healthcare and research ethics
6. Heart Muscle Cells Regenerate in Kids, Research Shows
7. Research Reveals Which Learning Methods Get an A
8. Researchers use iPSCs to define optimal treatment for managing life-threatening arrhythmias
9. Dental Implants Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
10. UT Arlington receives Grand Challenges Explorations grant for research in global health
11. Book co-authored by USF Nursing Dean named 2012 Nursing Research Book of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... VA (PRWEB) , ... February 20, 2017 , ... Silverado ... Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, Virginia. ... 2018 on a site just outside of Old Town. , The three-story community ...
(Date:2/20/2017)... ... February 20, 2017 , ... Clearwave is the ... on the Posiflex XT-series of touch screen terminals. Both companies will be showcasing ... Florida. The terminal provider Posiflex is helping to bridge the gap between healthcare ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... as an employee health benefit for companies that want to help members of ... providers, employees will have access to Watson’s suite of oncology offerings for insights ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and ... Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New York ... needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in a ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Rosacea market? ...
(Date:2/20/2017)... Taiwan , Feb. 21, 2017 Taiwan ... leading provider of non-invasive vital signs sensing solutions, today ... industry,s first finger-free wrist pulse oximeter, the oCare TM ... the wearable healthcare and medical devices space.  ... 100, provides a non-invasive, simple and reliable method to ...
(Date:2/20/2017)...  This Report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing ... Forms, and Liquid & Semi-solid Dosage Forms. The report provides separate ... Japan , Europe , ... the full report: http://www.reportlinker.com/p04707109-summary/view-report.html ... Annual estimates and forecasts are provided for ...
Breaking Medicine Technology: